Imugene Ltd · ASX:IMU
Imugene — Shareholder Meeting (November 2022)
15 slides from Imugene's shareholder meeting presentation, Nov 17, 2022
Slide 1: Developing Cancer Immunotherapies - AGM November 2022
For personal use only ASX: IMU Developing Cancer Immunotherapies AGM November 2 0 2 2
Slide 2: Disclaimer
DISCLAIMER For personal use only 1. The information in this presentation does not constitute personal investment associated persons or subsidiaries are liable for any direct, indirect or advice. The presentation is not intended to be comprehensive or provide all consequential loss or damage suffered
Slide 3: 2022 Imugene Summary
2022 IMUGENE SUMMARY January 2023 For personal use only HER-Vaxx HERIZON December and nextHERIZON at September 2022 2021 ASCO GI August 2022 Raises A$80m in CHECKvacc Phase 1 May 2022 institutional presenting at SABCS CHECKvacc Phase 1 placement January 2022 First patient dosed trial reaches in VAXI
Slide 4: Investment Highlights
INVESTMENT HIGHLIGHTS For personal use only MARKET CAPITALISATION 16th Nov 2022 A$1.29B CASH AS OF 30th Sep 2022 A$163.8M CF33 B-Cell Immunotherapies CHECKvacc Oncolytic Virus onCARlytics HER-Vaxx 3 Breast (TNBC) DISEASE AREAS PLATFORM TECHNOLOGIES Lung (NSCLC) Gastric VAXINIA CF33-CD19 Gastroesopha
Slide 5: Imugene's Management Team
IMUGENE’S MANAGEMENT TEAM Experienced management team with significant clinical development expertise For personal use only Leslie Chong Dr Nick Ede Dr Anthony Good Ursula McCurry Bonnie Nixon Amanda Seiz Chief Executive Chief Technology Snr VP of Snr VP of Clinical Snr Project Snr Director of Offic
Slide 6: HER-Vaxx 2022 Year in Review
HER-Vaxx 2022 YEAR IN REVIEW OVERALL SURVIVAL HERIZON: ENDPOINT Final OS Readout For personal use only Phase 2 Final OS Readout with positive HER-Vaxx + Chemo Treatment overall survival Chemo Only Poster at ESMO World GI Sample Size 19 17 Oral presentation at ESMO ASIA Events 15 17 Oral pres
Slide 7: PD1-Vaxx 2022 Year in Review
PD1-Vaxx 2022 YEAR IN REVIEW For personal use only IMPRINTER: Completed Phase 1a monotherapy dose escalation Clinical trial supply agreement with Roche to evaluate PD1-Vaxx in combination with Tecentriq® Abstract was published for ASCO 2022 Poster presented at 2022 World Conference on Lung C
Slide 8: CHECKvacc 2022 Year in Review
CHECKvacc 2022 YEAR IN REVIEW Phase 1, single centre, dose-escalation study in For personal use only triple negative breast cancer at COH – FDA approval, first patient dosed, cohort 3 open Publication of abstract at American Society of Clinical Oncology Annual (ASCO) Annual Meeting Abstract ac
Slide 9: VAXINIA 2022 Year in Review
VAXINIA 2022 YEAR IN REVIEW Phase 1 MAST Study: For personal use only FDA IND Approval Dose Administration VAXINIA Monotherapy Dose First Patient Dosed IT Cohort 1 (Parallel Groups) Escalation n=52-100 OGTR License Granted IT IV IT First Patient Dosed IV Cohort 1 IT Administration COHORT 3-6
Slide 10: onCARlytics 2022 Year in Review
onCARlytics 2022 YEAR IN REVIEW Showcased three abstracts at SITC : For personal use only Combination immunotherapy using a novel chimeric oncolytic virus to redirect CD19 bispecific T cell engagers to target solid tumors CF33-CD19T oncolytic virus (onCARlytics) in combination with off-the-shelf
Slide 11: Professor Yuman Fong
PROFESSOR YUMAN FONG The Sangiacomo Family Chair in Surgical Oncology and chair of The City of Hope Dept of Surgery is an internationally recognized expert in liver and pancreatic cancer. He has developed many new surgical techniques and instruments. He For personal use only helped usher in robotic
Slide 12: Dr Saul Priceman
DR SAUL PRICEMAN Saul Priceman, Ph.D., is an assistant professor and associate director of Translational Sciences & Technologies in the T Cell Therapeutics Research Laboratories at City of Hope, as well as a trained tumor immunologist with expertise in T cell biology and cancer immunotherapy. He is
Slide 13: Milestones
MILESTONES TECHNOLOGY MILESTONE onCARlytics Phase 1 - 1st Patient Dosed For personal use only HER-Vaxx nextHERIZON Arm 2 Cleared CHECKvacc Sponsored Study FDA IND VAXINIA Combination – 1st Patient Dosed onCARlytics FDA IND PD1-Vaxx Combination - 1st Patient Dosed NEXT 1 -12 MONTHS CHECKvacc Cohort 3
Slide 14: Financial Summary
FINANCIAL SUMMARY PUBLIC MARKET OVERVIEW (16 Nov 22) SHARE PRICE PERFORMANCE For personal use only Share Price A$0.205 52 week range $0.13 - $0.625 Market Capitalisation1 A$1.29B Cash equivalents (30 Sep 22) A$163.8M Enterprise Value A$1.07B TOP 5 SHAREHOLDERS (AS AT 11 NOVEMBER 2022)` JP Morgan Nom
Slide 15: Contact
Contact For personal use only info@imugene.com www.imugene.com ASX: IMU